Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The FDA-approved drug nitazoxanide is a potent inhibitor of human seasonal coronaviruses acting at postentry level: effect on the viral spike glycoprotein

29 Aug 2023

Abstract excerpt

Coronaviridae is recognized as one of the most rapidly evolving virus family as a consequence of the high genomic nucleotide substitution rates and recombination. The family comprises a large number of enveloped, positive-sense single-stranded RNA viruses, causing an array of diseases of varying severity in animals and humans. To date, seven human coronaviruses (HCoV) have been identified, namely HCoV-229E,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Virus Infections Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37705731
DOI: 10.3389/fmicb.2023.1206951

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The FDA-approved drug nitazoxanide is a potent inhibitor of human seasonal coronaviruses acting at postentry level: effect on the viral spike glycoproteinPMID 37705731Read ↗

The FDA-approved drug nitazoxanide is a potent inhibitor of human seasonal coronaviruses acting at postentry level: effect on the viral spike glycoproteinSemantic proximity Read ↗

The oral drug nitazoxanide restricts SARS-CoV-2 infection and attenuates disease pathogenesis in Syrian hamstersSemantic proximity Read ↗

The recent outbreaks of human coronaviruses: A medicinal chemistry perspectiveSemantic proximity Read ↗

In Vitro Inhibition of SARS-CoV-2 Infection by Bromhexine hydrochlorideSemantic proximity Read ↗

Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike proteinSemantic proximity Read ↗

Seasonal Human Coronaviruses OC43, 229E, and NL63 Induce Cell Surface Modulation of Entry Receptors and Display Host Cell-Specific Viral Replication KineticsSemantic proximity Read ↗

Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronavirusesSemantic proximity Read ↗

Seasonal human coronaviruses OC43, 229E, and NL63 induce cell surface modulation of entry receptors and display host cell-specific viral replication kineticsSemantic proximity Read ↗

Methylene Blue Is a Nonspecific Protein-Protein Interaction Inhibitor with Potential for Repurposing as an Antiviral for COVID-19Semantic proximity Read ↗

Astrovirus Replication Is Inhibited by Nitazoxanide In Vitro and In VivoSemantic proximity Read ↗

Repurposing Cilnidipine as an Entry Inhibitor Against Crimean–Congo Haemorrhagic Fever Pseudovirus InfectionSemantic proximity Read ↗

Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.